Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05925764 | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma | recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05400070 | Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | active not recruiting | Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | recruiting | Phase 1 / Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645743 | Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma | not yet recruiting | — | 1,100 | The Third Affiliated Hospital of Kunming Medical College.OTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646770 | SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)(SELTIC) | not yet recruiting | N/A | 400 | Istanbul University - CerrahpasaOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04605146 | Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy(MONITOR) | recruiting | N/A | 100 | Hospices Civils de LyonOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643910 | A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | not yet recruiting | N/A | 12 | BioSyngen Pte LtdINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT04806399 | Improving Utilization of Lung Cancer Screening in Underserved PA Populations | active not recruiting | N/A | 2,500 | American College of RadiologyOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05902559 | Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks(ALPINE) | recruiting | — | 10,000 | University College, LondonOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06028412 | Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study | enrolling by invitation | N/A | 660 | Xiaolong Yan, Dr.OTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06607770 | Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers | recruiting | Phase 1 / Phase 2 | 20 | Zhou ChengzhiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05878964 | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.(SkinHealth) | recruiting | — | 420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06628102 | Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study(IDEAL) | recruiting | N/A | 3,600 | British Columbia Cancer AgencyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06603675 | Microplastics in the Human Respiratory System | not yet recruiting | — | 100 | Wielkopolskie Centrum Pulmonologii i TorakochirurgiiOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06626178 | Development of an Artificial Intelligence Model for the Identification and Prevention of Smoking-related Diseases.(ARIA) | recruiting | N/A | 2,840 | Scientific Institute San RaffaeleOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06623487 | The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06247163 | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.(PET-ART) | recruiting | — | 30 | University Hospital, EssenOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616909 | Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences | active not recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06607796 | Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | recruiting | Phase 3 | 180 | Zhou ChengzhiOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05557552 | Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer | recruiting | N/A | 56 | Ruijin HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05974475 | MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer(MONDRIAN) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06607926 | Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC | not yet recruiting | N/A | 40 | Xuanwu Hospital, BeijingOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06608160 | 68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer. | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05014464 | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase) | recruiting | Phase 2 | 90 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05991193 | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer | recruiting | — | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06355609 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW(WUKONG-32-RW) | recruiting | Phase 2 | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04324125 | Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04324151 | Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04777175 | A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer | recruiting | — | 186 | Yongchang ZhangOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05379803 | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | recruiting | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 21, 2024source: clinicaltrials